These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 24382388)

  • 1. Clinical development of demethylating agents in hematology.
    Navada SC; Steinmann J; Lübbert M; Silverman LR
    J Clin Invest; 2014 Jan; 124(1):40-6. PubMed ID: 24382388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L; Greil R
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
    Link PA; Baer MR; James SR; Jones DA; Karpf AR
    Cancer Res; 2008 Nov; 68(22):9358-66. PubMed ID: 19010910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNMT3A alterations associated with myeloid malignancies dictate differential responses to hypomethylating agents.
    Casellas Román HL; Venugopal K; Feng Y; Shabashvili DE; Posada LM; Li J; Guryanova OA
    Leuk Res; 2020 Jul; 94():106372. PubMed ID: 32445940
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
    Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
    Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
    Hackanson B; Robbel C; Wijermans P; Lübbert M
    Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
    Estey EH
    Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical update on hypomethylating agents.
    Duchmann M; Itzykson R
    Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
    Lowder JN; Taverna P; Issa JP
    Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
    [No Abstract]   [Full Text] [Related]  

  • 10. A pharmacodynamic assay to monitor treatment with the hypomethylating cytosine analogs, decitabine and azacitidine.
    Jacobberger JW; Woost PG
    Methods Cell Biol; 2024; 186():131-150. PubMed ID: 38705597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia.
    Yun H; Damm F; Yap D; Schwarzer A; Chaturvedi A; Jyotsana N; Lübbert M; Bullinger L; Döhner K; Geffers R; Aparicio S; Humphries RK; Ganser A; Heuser M
    Haematologica; 2014 Sep; 99(9):1456-64. PubMed ID: 24895338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review: recent clinical trials in epigenetic therapy.
    Oki Y; Issa JP
    Rev Recent Clin Trials; 2006 May; 1(2):169-82. PubMed ID: 18473969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.
    Mahfouz RZ; Jankowska A; Ebrahem Q; Gu X; Visconte V; Tabarroki A; Terse P; Covey J; Chan K; Ling Y; Engelke KJ; Sekeres MA; Tiu R; Maciejewski J; Radivoyevitch T; Saunthararajah Y
    Clin Cancer Res; 2013 Feb; 19(4):938-48. PubMed ID: 23287564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cancer‑testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivo.
    Zhou J; Li Y; Yao Y; Wang L; Gao L; Gao X; Luo X; Li J; Jiang M; Zhou M; Wang L; Yu L
    Mol Med Rep; 2013 Nov; 8(5):1549-55. PubMed ID: 24002123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML.
    Lund K; Cole JJ; VanderKraats ND; McBryan T; Pchelintsev NA; Clark W; Copland M; Edwards JR; Adams PD
    Genome Biol; 2014 Aug; 15(8):406. PubMed ID: 25315154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic evaluation of decitabine for the treatment of leukemia.
    Bryan J; Kantarjian H; Garcia-Manero G; Jabbour E
    Expert Opin Drug Metab Toxicol; 2011 May; 7(5):661-72. PubMed ID: 21500965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
    Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G
    Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decitabine in the treatment of myelodysplastic syndromes.
    Santos FP; Kantarjian H; Garcia-Manero G; Issa JP; Ravandi F
    Expert Rev Anticancer Ther; 2010 Jan; 10(1):9-22. PubMed ID: 20014881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.
    Metzeler KH; Walker A; Geyer S; Garzon R; Klisovic RB; Bloomfield CD; Blum W; Marcucci G
    Leukemia; 2012 May; 26(5):1106-7. PubMed ID: 22124213
    [No Abstract]   [Full Text] [Related]  

  • 20. Demethylating agents in myeloid malignancies.
    Garcia-Manero G
    Curr Opin Oncol; 2008 Nov; 20(6):705-10. PubMed ID: 18841054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.